山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00719 山东新华制药股份

休市中 10-02 16:08:07

5.800

-0.015

-0.26%

最高5.835	最低5.505	成交量21.20万
今开5.680	昨收5.815	日振幅5.68%
总市值40.43亿	流通市值11.31亿	总股本6.97亿
成交额120.30万	换手率0.11%	流通股本1.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.8,"timestamp":1790928487425,"preClose":5.815,"halted":0,"volume":212000,"delay":0,"changeRate":-0.002579535683577054,"floatShares":195000000,"shares":697000000,"eps":0.49103985686371454,"marketStatus":"休市中","change":-0.015,"latestTime":"10-02 16:08:07","open":5.68,"high":5.835,"low":5.505,"amount":1203024,"amplitude":0.05675,"askPrice":5.8,"askSize":10000,"bidPrice":5.65,"bidSize":88000,"shortable":0,"etf":0,"ttmEps":0.36295678677087995,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":7,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.815,"dividendRate":0.029813,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.20092501328958007,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":14.6,"timestamp":1790751600000,"preClose":13.98,"halted":0,"volume":55215200,"delay":0,"premium":"-66.02"}},"requestUrl":"/m/hq/s/00719","defaultTab":"news","newsList":[{"id":"1129190178","title":"山东新华制药（00719）副总经理刘雪松辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1129190178","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129190178?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:56","pubTimestamp":1790672187,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司9月29日公告称，公司董事会于2026年9月29日收到副总经理刘雪松的书面辞职报告。刘雪松因工作变动原因，辞去公司副总经理及在公司担任的其他一切职务，辞职自送达董事会之日起生效。\\n\\n公告显示，刘雪松在任职期间与董事会无意见分歧，亦不存在需提请股东注意的其他事项。\\n\\n截至公告披露日，刘雪松持有公司A股223,100股。\\n\\n董事会对刘雪松先生在任期间所作出的贡献表示感谢。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671629736","title":"山东新华制药股份(00719.HK)：刘雪松辞任副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2671629736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671629736?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:53","pubTimestamp":1790672016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110097","title":"山东新华制药股份(00719)：A股股票交易异常波动 前期披露的信息不存在需要更正、补充之处","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669110097?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:31","pubTimestamp":1790069478,"startTime":"0","endTime":"0","summary":"针对公司股票异常波动，公司对有关事项进行了核查，有关情况说明如下： 1、经核查，公司前期披露的信息不存在需要更正、补充之处。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["83130","03130","83188","00719","399300","159982","82846","02846","03188","02827","BK1515","BK1147","BK1191","07233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145497097","title":"山东新华制药：A股三日累涨偏离20% 公司称无未披露重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1145497097","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145497097?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:30","pubTimestamp":1790069433,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司9月22日公告称，其A股股票于2026年9月18日、9月21日及9月22日连续三个交易日收盘价格涨幅偏离值累计达到20%，根据深圳证券交易所相关规定，构成股票交易异常波动。公司表示，经内部核查及向控股股东、实际控制人问询，近期经营情况及内外部经营环境未发生重大变化，亦不存在应披露而未披露的重大事项，控股股东和实际控制人在上述期间未买卖公司股票。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192086388","title":"山东新华制药股份2026年上半年营收43.58亿元，经调整净利润1.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192086388","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192086388?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:48","pubTimestamp":1790066919,"startTime":"0","endTime":"0","summary":"2026年上半年，山东新华制药股份公告显示，公司实现营业收入约43.58亿元，同比下降6.06%；经调整后净利润约1.47亿元，同比下降30.14%。本期销售费用约1.68亿元，同比下降2.82%；管理费用约2.07亿元，同比下降3.80%；研发投入约1.92亿元，同比下降5.16%；财务费用则增长显著，同比增长208.72%。报告期内，经营活动产生的现金流量净额约为1.61亿元，同比下降31.40%。公司继续在研发端保持投入，报告期内研发占比维持在较高水平，为后续新产品及创新药布局提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份2026年上半年营收43.58亿元，经调整净利润1.47亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669580151","title":"A股收评：超4500股上涨！沪指涨0.97%，创新药、地产板块爆发，“华字辈”现涨停潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2669580151","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669580151?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:05","pubTimestamp":1789974303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0102","BK0188","000001","LU1993786604.SGD","LU0501845795.SGD","BK0164","LU0067412154.USD","BK0273","BK0095","BK0190","BK0012","BK0028","BK0239","BK0187","LU0072913022.USD","00719","BK0113","BK0216","600721","000756","BK0278","LU1226287529.USD","LU1781817850.SGD","IE00B0JY6N72.USD","LU1580142542.USD","600664","BK0201","LU1655091616.SGD","BK0183","002285","LU0880133367.SGD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06699","BK1191","BK1583","03600","01530","BK1600","00719","BK1593","BK1161","BK1515","HK0000165453.HKD","06826","02196","00460","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669710136","title":"港股异动 | 山东新华制药股份(00719.HK)早盘涨超8% 左卡尼汀口服溶液等获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2669710136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669710136?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:54","pubTimestamp":1789955673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187346461","title":"山东新华制药（00719）子公司获盐酸多奈哌齐口崩片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1187346461","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187346461?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:07","pubTimestamp":1789722468,"startTime":"0","endTime":"0","summary":"2026年9月18日，山东新华制药股份公告称，其全资子公司山东淄博新达制药有限公司已收到国家药品监督管理局核准签发的盐酸多奈哌齐口崩片《药品注册证书》。新达制药于2025年2月提交上市许可申请，2026年9月获批注册。盐酸多奈哌齐口崩片适用于轻度、中度或重度阿尔茨海默病症状的治疗，已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种。公司表示，本次获批有利于丰富其中枢神经领域产品系列，提升综合竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198107025","title":"山东新华制药（00719）获得硫酸镁钠钾口服用浓溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1198107025","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198107025?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:06","pubTimestamp":1789722363,"startTime":"0","endTime":"0","summary":"9月18日，山东新华制药股份有限公司公告称，公司已收到国家药品监督管理局签发的硫酸镁钠钾口服用浓溶液《药品注册证书》。该品种注册分类为化学药品4类，剂型为口服溶液剂，规格为176ml：硫酸镁3.276g、硫酸钠17.510g、硫酸钾3.130g，为处方药。硫酸镁钠钾口服用浓溶液已被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》乙类范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137989613","title":"山东新华制药（00719）获批左卡尼汀口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1137989613","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137989613?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:06","pubTimestamp":1789722363,"startTime":"0","endTime":"0","summary":"2026年9月18日，山东新华制药股份有限公司公告称，其收到国家药品监督管理局核准签发的左卡尼汀口服溶液《药品注册证书》，标志着该产品正式获准在境内生产并上市销售。本次获批的左卡尼汀口服溶液剂型为口服溶液剂，规格为10ml：1g，药品类别为处方药，注册分类为化学药品4类。公司表示，左卡尼汀口服溶液的获批将进一步丰富其口服代谢调节制剂产品线，提升市场竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668419779","title":"山东新华制药股份(00719)：获得左卡尼汀口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668419779","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668419779?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:03","pubTimestamp":1789722239,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份 发布公告，近日，公司收到国家药品监督管理局核准签发的左卡尼汀口服溶液《药品注册证书》。2024年12月，新华制药向国家药品监督管理局药品审评中心递交左卡尼汀口服溶液境内生产药品上市许可注册申报资料并获受理，2026年9月获得《药品注册证书》，审评结论为批准注册。根据相关统计数据，2025年中国公立医疗机构左卡尼汀口服溶液销售额约为人民币4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)：获得左卡尼汀口服溶液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00719","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182098371","title":"新华制药硫酸镁、硫酸钠、硫酸钾浓溶液口服液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1182098371","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182098371?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:01","pubTimestamp":1789722068,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司宣布，其研发的硫酸镁、硫酸钠、硫酸钾浓溶液口服液已成功获得药品注册证书。此举标志着该公司在医药领域的又一重要进展，进一步丰富了其产品线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","000756","00719","BK0239","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668941644","title":"山东新华制药股份(00719.HK)子公司获得盐酸多奈哌齐口崩片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668941644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668941644?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:00","pubTimestamp":1789722002,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101995774","title":"新华制药获国家药监局批准盐酸多奈哌齐片注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1101995774","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101995774?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:59","pubTimestamp":1789721950,"startTime":"0","endTime":"0","summary":"新华制药（Shandong Xinhua Pharmaceutical Co）传来最新进展——其盐酸多奈哌齐片已获得国家药品监督管理局的注册批准。这标志着该产品在合规性与临床适用性上通过了监管层的严格审视，距正式投放市场更近一步。据悉，该药品此番获批，为公司产品线再添新的增长点。此次审批的通过，也为新华制药在神经系统用药领域的战略布局夯实了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK0164","00719","000756","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103544505","title":"新华制药旗下新猫制药获盐酸多奈哌齐片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1103544505","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103544505?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:59","pubTimestamp":1789721949,"startTime":"0","endTime":"0","summary":"新华制药（000756.SZ；00719.HK）旗下新猫制药近日取得盐酸多奈哌齐片的药品注册证书。这一进展标志着该公司在神经系统药物领域的产品线再添新丁。盐酸多奈哌齐片主要用于治疗阿尔茨海默病相关症状，市场前景广阔。此次获证，无疑为新华制药抢占该细分市场份额奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719","000756","BK0239","BK0164","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185603184","title":"山东新华制药股份更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1185603184","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185603184?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:06","pubTimestamp":1788221180,"startTime":"0","endTime":"0","summary":"山东新华制药股份于2026年9月1日披露2026年8月股份变动月报表。报告期内，公司普通股包括在香港联交所上市的H股及未在香港联交所上市的A股，股本结构呈现总体稳定。数据显示，截至2026年8月31日，公司H股上月底与本月底均为195,000,000股，A股上月底与本月底均为501,683,435股。截至2026年8月31日，公司已确认满足香港联交所相关规则要求，并承诺严格遵守香港联交所《上市规则》及其他法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146339826","title":"山东新华制药：子公司阿奇霉素片通过一致性评价，瞄准年销6.7亿元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1146339826","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146339826?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165536,"startTime":"0","endTime":"0","summary":"2026年8月31日，山东新华制药股份有限公司公告称，其全资子公司山东淄博新达制药有限公司于2026年8月收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿奇霉素片已通过仿制药质量和疗效一致性评价。根据相关统计数据，2025年中国公立医疗机构阿奇霉素片销售额约为人民币6.7亿元。公司称，本次通过一致性评价有利于提升产品市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116866655","title":"山东新华制药股份有限公司（00719）获批盐酸达泊西汀片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1116866655","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116866655?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:36","pubTimestamp":1787906215,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月28日公告称，公司已收到国家药品监督管理局核准签发的盐酸达泊西汀片《药品注册证书》。2025年4月，公司向国家药品监督管理局药品审评中心递交境内生产上市许可注册申报材料并获受理；2026年8月获批注册。公告援引数据显示，2025年中国公立医疗机构达泊西汀销售额约为人民币10.3亿元。公司表示，盐酸达泊西汀片的获批将进一步丰富其制剂产品系列并提升市场竞争力。公告日期：2026年8月28日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101666638","title":"山东新华制药（00719）董事会审议通过2026年中期报告及衍生品交易等四项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1101666638","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101666638?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648607,"startTime":"0","endTime":"0","summary":"山东新华制药股份有限公司8月25日公告称，公司第十一届董事会第十二次会议已于2026年8月25日在山东省淄博市高新区鲁泰大道1号公司会议室召开。会议通知于2026年8月11日以电邮形式发出，应到会董事8名，实际参会8名，会议由董事长贺同庆主持，召集程序符合相关法律法规及公司章程规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.032},{"period":"3month","weight":0.0264},{"period":"6month","weight":-0.0666},{"period":"1year","weight":-0.1839},{"period":"ytd","weight":-0.0935}],"compareEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":-0.0529},{"period":"3month","weight":0.0266},{"period":"6month","weight":-0.0456},{"period":"1year","weight":-0.1215},{"period":"ytd","weight":-0.0647}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂及化工产品的开发、制造和销售的中国公司。该公司运营三个分部。化学原料药分部主要从事咖啡因系列、布洛芬系列、阿司匹林系列、多巴系列、巴比妥系列及吡哌酸等解热镇痛类原料药的开发、制造及销售。制剂分部主要从事吡哌酸片、安痛定及尼莫地平片等片剂、针剂及胶囊剂等制剂的开发、制造及销售。医药中间体及其他产品分部主要从事医药中间体及其他产品的开发、制造及销售。该公司主要在中国国内市场及美洲和欧洲等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.012135},{"month":2,"riseRate":0.766667,"avgChangeRate":0.099902},{"month":3,"riseRate":0.433333,"avgChangeRate":-0.007748},{"month":4,"riseRate":0.7,"avgChangeRate":0.100629},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.000855},{"month":6,"riseRate":0.433333,"avgChangeRate":-0.005711},{"month":7,"riseRate":0.6,"avgChangeRate":0.01986},{"month":8,"riseRate":0.275862,"avgChangeRate":-0.043444},{"month":9,"riseRate":0.37931,"avgChangeRate":-0.016386},{"month":10,"riseRate":0.433333,"avgChangeRate":0.008631},{"month":11,"riseRate":0.551724,"avgChangeRate":0.012197},{"month":12,"riseRate":0.586207,"avgChangeRate":0.023647}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}